Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.

Gerald Willimsky | Christin Beier | Lena Immisch | George Papafotiou | Vivian Scheuplein | Andrean Goede | Hermann-Georg Holzhütter | Thomas Blankenstein | Peter M Kloetzel
eLife | 2021

Proteasome-catalyzed peptide splicing (PCPS) of cancer-driving antigens could generate attractive neoepitopes to be targeted by T cell receptor (TCR)-based adoptive T cell therapy. Based on a spliced peptide prediction algorithm, TCRs were generated against putative KRASG12V- and RAC2P29L-derived neo-splicetopes with high HLA-A*02:01 binding affinity. TCRs generated in mice with a diverse human TCR repertoire specifically recognized the respective target peptides with high efficacy. However, we failed to detect any neo-splicetope-specific T cell response when testing the in vivo neo-splicetope generation and obtained no experimental evidence that the putative KRASG12V- and RAC2P29L-derived neo-splicetopes were naturally processed and presented. Furthermore, only the putative RAC2P29L-derived neo-splicetopes was generated by in vitro PCPS. The experiments pose severe questions on the notion that available algorithms or the in vitro PCPS reaction reliably simulate in vivo splicing and argue against the general applicability of an algorithm-driven 'reverse immunology' pipeline for the identification of cancer-specific neo-splicetopes.

Pubmed ID: 33875134

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Dryad Digital Repository (tool)

RRID:SCR_005910

International, curated, digital repository that makes the data underlying scientific publications discoverable, freely reusable, and citable. Particularly data for which no specialized repository exists. Provides the infrastructure for, and promotes the re-use of, data underlying the scholarly literature. Governed by a nonprofit membership organization. Membership is open to any stakeholder organization, including but not limited to journals, scientific societies, publishers, research institutions, libraries, and funding organizations. Most data are associated with peer-reviewed articles, although data associated with non-peer reviewed publications from reputable academic sources, such as dissertations, are also accepted. Used to validate published findings, explore new analysis methodologies, repurpose data for research questions unanticipated by the original authors, and perform synthetic studies.UC system is member organization of Dryad general subject data repository.

View all literature mentions

PeproTech (tool)

RRID:SCR_006802

An Antibody supplier

View all literature mentions

FlowJo (tool)

RRID:SCR_008520

Software for single-cell flow cytometry analysis. Its functions include management, display, manipulation, analysis and publication of the data stream produced by flow and mass cytometers.

View all literature mentions

QIAGEN (tool)

RRID:SCR_008539

A commercial organization which provides assay technologies to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.

View all literature mentions

BD Biosciences (tool)

RRID:SCR_013311

An Antibody supplier

View all literature mentions

SW480 (tool)

RRID:CVCL_0546

Cell line SW480 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

AsPC-1 (tool)

RRID:CVCL_0152

Cell line AsPC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (tool)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Capan-1 (tool)

RRID:CVCL_0237

Cell line Capan-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

CFPAC-1 (tool)

RRID:CVCL_1119

Cell line CFPAC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H441 (tool)

RRID:CVCL_1561

Cell line NCI-H441 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

K-562 (tool)

RRID:CVCL_0004

Cell line K-562 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MCF-7 (tool)

RRID:CVCL_0031

Cell line MCF-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

SW620 (tool)

RRID:CVCL_0547

Cell line SW620 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

624-mel (cell line)

RRID:CVCL_8054

Cell line 624-mel is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions